Leerink Partnrs Issues Pessimistic Outlook for GPCR Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR) – Leerink Partnrs decreased their FY2024 earnings per share estimates for Structure Therapeutics in a report released on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of ($0.76) for the year, down from their previous estimate of ($0.59). The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ Q4 2024 earnings at ($0.20) EPS, FY2026 earnings at ($0.94) EPS, FY2027 earnings at ($0.85) EPS and FY2028 earnings at ($0.86) EPS.

Several other brokerages have also commented on GPCR. Morgan Stanley began coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. JMP Securities dropped their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Finally, HC Wainwright assumed coverage on shares of Structure Therapeutics in a research report on Wednesday. They set a “buy” rating and a $80.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $85.67.

Structure Therapeutics Price Performance

Shares of GPCR opened at $31.24 on Friday. The business has a 50-day moving average of $37.46 and a 200-day moving average of $39.32. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -42.22 and a beta of -3.41. Structure Therapeutics has a 1 year low of $26.61 and a 1 year high of $63.30.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Franklin Resources Inc. grew its holdings in Structure Therapeutics by 9.4% during the third quarter. Franklin Resources Inc. now owns 706,106 shares of the company’s stock worth $30,991,000 after buying an additional 60,397 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after acquiring an additional 312 shares during the last quarter. Barclays PLC grew its stake in shares of Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock worth $3,562,000 after acquiring an additional 31,815 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in shares of Structure Therapeutics by 35.6% in the third quarter. Nomura Asset Management Co. Ltd. now owns 29,429 shares of the company’s stock valued at $1,292,000 after purchasing an additional 7,719 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Structure Therapeutics during the third quarter worth about $1,787,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.